As of May 29, 2025, Albireo Pharma Inc (ALBO) reports a ROE (Return on Equity) of -19.38%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Albireo Pharma Inc's ROE (Return on Equity)
Over recent years, Albireo Pharma Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2021-12-31 | -19.38% |
| 2020-12-31 | -59.40% |
| 2019-12-31 | -67.30% |
| 2018-12-31 | -37.61% |
| 2017-12-31 | -37.38% |
This slight upward trend highlights how Albireo Pharma Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Albireo Pharma Inc's ROE (Return on Equity) to Peers
To better understand Albireo Pharma Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Albireo Pharma Inc (ALBO) | -19.38% |
| Abbvie Inc (ABBV) | 128.66% |
| Amgen Inc (AMGN) | 69.59% |
| Regeneron Pharmaceuticals Inc (REGN) | 15.03% |
| AVROBIO Inc (AVRO) | 12.83% |
| Precision BioSciences Inc (DTIL) | 12.71% |
Compared to its competitors, Albireo Pharma Inc's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.